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Introduction
Mutations in the LMNA gene have been shown to segregate with a wide spectrum of phenotypes, known as lamiopathies [10] , which might manifest as muscular dystrophy, cardiomyopathy, peripheral neuropathy, lipodystrophy, or premature ageing syndromes. In a large cohort of patients with LMNA mutations reported to date, only in few patients a "double" phenotype of axonal neuropathy coexisting with muscular dystrophy [1, 5] or dilated cardiomyopathy [4] was reported. In this study we present a patient with genetically confirmed Emery-Dreifuss dystrophy type 2 (EDMD2), who additionally had late-onset mild, distal, axonal neuropathy. The coexistence of axonal neuropathy and EDMD2 might either result from a single LMNA mutation or have a bigenic background. By analyzing of five genes involved in pathogenesis of polyneuropathy, i.e. peripheral myelin protein 22 (PMP22), ganglioside-induced differentiation-associated protein 1 (GDAP1), gap junction β-1 protein (GJB1), myelin protein zero (MPZ) and mitofusin 2 (MFN2) genes, we attempted to elucidate the molecular background of axonal polyneuropathy in our EDMD2 patient. Emery-Dreifuss muscular dystrophy type 2 and polyneuropathy
Case report
A thirty-four-year-old female (III:6) presented because of slowly progressing walking difficulties and weakness and atrophy of arms and thigh muscles. Since childhood she had been very slim, physically weaker, and less agile than her peers (Fig. 1) . During adolescence frequent fainting occurred. Similar clumsy walking was seen in the proband's father (II:4) and her grandmother (I:1); however, they were not examined neurologically. In addition, both relatives had a pacemaker implanted due to conduction disturbances, and the same cardiac problem occurred in the patient's uncle (II:2), who otherwise did not have any skeletal muscle disease. All three of these persons died suddenly at the age of 58 years (II:4), 62 years (II:2), and 66 years (I:1), respectively. Awareness of positive family history for a life-threatening cardiac disease and muscle symptoms being a cause of progressive physical disability were the main reasons for the proband to seek medical attention. Neurological examination revealed atrophy of arms, thighs, and calf muscles, weakness of proximal muscles with Gowers' sign, iliac asymmetry, absence of knee and ankle reflexes, spine rigidity with lumbar hyperlordosis, and slight elbow, knee, and ankle contractures. Superficial sensation was decreased in distal parts of lower limbs ("short socks"), while vibration sensation was normal. 24-hour electrocardiogram (ECG) monitoring revealed numerous episodes of supraventricular tachycardia and periodical atrioventricular block grade I. Echocardiogram was normal. On electroneurography (ENG) the stimulation of the left peroneal nerve revealed trace response in the distal point (0.1 mV; velocity not recordable) with no response near the fibula head; the stimulation of the right peroneal nerve revealed prolongation of the motor response latency (10.4 ms). Nerve conduction velocities were slightly decreased in the motor fibres of tibial and sural nerves, being 42.5 m/s and 45.2 m/s, respectively. Clinically affected members (I:1, II:2, II:4) were unavailable for ENG/electromyography (EMG), but the examination was normal in the patient's aunt (II:6) and mother (II:3). Once written informed consent and Bioethical Committee approval had been received, we performed genetic analysis in the proband and in her unaffected mother (II:3) and aunt (II:6). Genomic DNA was extracted from peripheral blood lymphocytes using a saltingout procedure. All 12 exons of LMNA and exon-intron junctions were amplified by PCR, sequenced using the Big Dye Terminator Sequencing Ready Reaction kit (Applied Biosystems), and analysed on an ABI PRISM 373 fluorescent DNA sequencer (Applied Biosystems). Analysis of the LMNA gene revealed a heterozygous missense mutation c.1130G>A (p.R377H) (Fig. 2) . Analysis of PMP22 did not reveal deletion/ duplication. Direct sequencing of GDAP1, GJB1, and MPZ did not reveal mutations. Sequence analysis of MFN2 showed a single nucleotide substitution c.1469+50G>T within the twelfth intron, not found either in the proband's unaffected mother (II:3) and aunt (II:6) nor in 100 healthy controls. To check whether it affects splicing, we extracted mRNA from blood lymphocytes and then obtained cDNA from mRNA, encompassing exons 12-13 of MFN2 gene. Polymerase chain reaction (PCR) with the designed primers: forward in 11 exon and reverse in 14 exon, resulted in synthesis of the 391 bp oligonucleotide, which had the same length in the proband and in 3 healthy controls. This might indicate that MFN2 variant c.1469+50G>T does not affect splicing (Fig. 3) .
Discussion
The coexistence of axonal polyneuropathy with muscular dystrophy/dilated cardiomyopathy has been shown only in a few patients [1, 4, 5] . Laminopathy with peripheral nerve involvement, associated with homozygous LMNA mutation p.R298C, was first described by De Sandre-Giovannoli et al. in 2002 [3] . There have been several reports of laminopathies with overlapping phenotype of axonal neuropathy and muscular dystrophy and/or cardiac involvement with autosomal dominant trait of inheritance. In 2004 Goizet et al. described a 55-year-old man and his 13-year-old daughter presenting axonal neuropathy, muscular dystrophy, cardiac involvement, and leukonychia, in whom LMNA mutation p.E33D was found [5] . Both patients had sensory abnormalities in distal lower limbs, while pes cavus, pelvic and distal muscle weakness was seen only in the older one. In 2005 Benedetti et al. reported a boy with LMNA mutation c.1711C>T, who had progressive distal and proximal muscle atrophy/weakness, causing him to be wheelchair bound; as well as pes equinovarus, which was corrected surgically, mildly impaired proprioceptive sensation and fat accumulation in the face and neck were seen [1] . A cardio-neurological form of laminopathy, associated with LMNA mutation c.1496delC, has been described in a 40-year-old man by Duparc et al. [4] . In addition to heart disease atrophy of quadriceps muscle, lack of reflexes, and contracted feet were found and ENG showed moderate axonal neuropathy. However, no molecular basis of EDMD2/Charcot-Marie-Tooth neuropathy (CMT) coexistence has been identified. The question remains unanswered: whether the phenotype in the presented case results from a single mutation within the LMNA gene or rather represents an overlapping syndrome associated with mutations in at least two genes. Our patient harbours a mutation in LMNA, c.1130G>A (p.R377H). This has been shown to segregate with phenotypes affecting skeletal and cardiac muscles, i.e. EDMD2 [8] , limb-girdle muscular dystrophy 1B (LGMD1B) [6] , isolated cardiomyopathy with conduction defects (DCM-CD) [7] , or qua driceps myopathy with DCM-CD [2] . No axonal neuropathy in EDMD2 was reported as being caused by R377H mutation in the LMNA gene. To elucidate the genetic background of the disease in our patient we analysed five genes: PMP22, GDAP1, GJB1, MPZ, and MFN2, causative for CMT disease. Heterozygous mutations in GDAP1 segregate with a mild form of axonal neuropathy with slow progression, resembling the clinical course observed in our patient [11] . Analysis of the GDAP1 gene in our patient did not reveal mutations. Also, no mutations in the coding sequence of PMP22, GJB1, and MPZ genes were found. The MFN2 gene is the most commonly mutated gene in autosomal dominant CMT2. Late onset, milder phenotype is associated either with intronic mutations or with mutations at the end of the coding sequence of the MFN2 gene [9] . We attempted to investigate the pathogenic status of the sequence variant c.1469+50G>T in MFN2; the analysis of cDNA showed that it probably did not affect splicing (Fig. 2) . We cannot definitively exclude that another unknown mutation caused the peripheral neuropathy observed in our patient. Polyneuropathy has never been reported in the context of the LMNA mutation p.R377H; therefore, bigenic molecular pathogenesis seems more likely in the presented case of EDMD2/CMT2. Initially we decided to sequence the late onset-CMT2-associated genes instead of exome sequencing analysis because hundreds of NGS-generated variants of unknown clinical relevance might be difficult to interpret. Since no mutations were detected in the analysed genes responsible for neuropathy, it seems that only wide genetic analysis could help to clarify the genetic basis of this case.
